EquitySector - HealthcareVery High Risk
Regular
NAV (27-Jun-25)
Returns (Since Inception)
Fund Size
₹2,691 Cr
Expense Ratio
1.94%
ISIN
INF769K01EA2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+17.50%
+15.33% (Cat Avg.)
3 Years
+23.50%
+24.26% (Cat Avg.)
5 Years
+21.73%
+20.68% (Cat Avg.)
Since Inception
+20.73%
— (Cat Avg.)
Equity | ₹2,673.31 Cr | 99.36% |
Others | ₹17.24 Cr | 0.64% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹306.9 Cr | 11.41% |
Divi's Laboratories Ltd | Equity | ₹205.82 Cr | 7.65% |
Aurobindo Pharma Ltd | Equity | ₹187.79 Cr | 6.98% |
Cipla Ltd | Equity | ₹167.54 Cr | 6.23% |
Apollo Hospitals Enterprise Ltd | Equity | ₹154.84 Cr | 5.76% |
Glenmark Pharmaceuticals Ltd | Equity | ₹147.68 Cr | 5.49% |
Lupin Ltd | Equity | ₹145.69 Cr | 5.41% |
Dr Reddy's Laboratories Ltd | Equity | ₹121.05 Cr | 4.50% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹111.58 Cr | 4.15% |
Cohance Lifesciences Ltd | Equity | ₹104.34 Cr | 3.88% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹81.02 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹78.32 Cr | 2.91% |
Wockhardt Ltd | Equity | ₹75.69 Cr | 2.81% |
Gland Pharma Ltd | Equity | ₹75.31 Cr | 2.80% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹75.24 Cr | 2.80% |
OneSource Specialty Pharma Ltd | Equity | ₹71.03 Cr | 2.64% |
Ipca Laboratories Ltd | Equity | ₹69.14 Cr | 2.57% |
Mankind Pharma Ltd | Equity | ₹67.1 Cr | 2.49% |
Sai Life Sciences Ltd | Equity | ₹66.72 Cr | 2.48% |
Alkem Laboratories Ltd | Equity | ₹66.23 Cr | 2.46% |
Fortis Healthcare Ltd | Equity | ₹65.9 Cr | 2.45% |
Syngene International Ltd | Equity | ₹47.02 Cr | 1.75% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹44.68 Cr | 1.66% |
Biocon Ltd | Equity | ₹32.37 Cr | 1.20% |
Alembic Pharmaceuticals Ltd | Equity | ₹29.46 Cr | 1.10% |
Sagility India Ltd | Equity | ₹20.79 Cr | 0.77% |
Treps | Cash - Repurchase Agreement | ₹20.68 Cr | 0.77% |
Deepak Nitrite Ltd | Equity | ₹19.09 Cr | 0.71% |
Neogen Chemicals Ltd | Equity | ₹17.3 Cr | 0.64% |
Laxmi Dental Ltd | Equity | ₹15.62 Cr | 0.58% |
Net Receivables / (Payables) | Cash | ₹-3.67 Cr | 0.14% |
Zydus Lifesciences Ltd | Equity | ₹2.02 Cr | 0.08% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.23 Cr | 0.01% |
Large Cap Stocks
32.77%
Mid Cap Stocks
37.27%
Small Cap Stocks
26.10%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,636.92 Cr | 98.01% |
Basic Materials | ₹36.39 Cr | 1.35% |
Standard Deviation
This fund
16.50%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
0.85
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since July 2018
ISIN INF769K01EA2 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹2,691 Cr | Age 7 years | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹1,95,338 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (27-Jun-25)
Returns (Since Inception)
Fund Size
₹2,691 Cr
Expense Ratio
1.94%
ISIN
INF769K01EA2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+17.50%
+15.33% (Cat Avg.)
3 Years
+23.50%
+24.26% (Cat Avg.)
5 Years
+21.73%
+20.68% (Cat Avg.)
Since Inception
+20.73%
— (Cat Avg.)
Equity | ₹2,673.31 Cr | 99.36% |
Others | ₹17.24 Cr | 0.64% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹306.9 Cr | 11.41% |
Divi's Laboratories Ltd | Equity | ₹205.82 Cr | 7.65% |
Aurobindo Pharma Ltd | Equity | ₹187.79 Cr | 6.98% |
Cipla Ltd | Equity | ₹167.54 Cr | 6.23% |
Apollo Hospitals Enterprise Ltd | Equity | ₹154.84 Cr | 5.76% |
Glenmark Pharmaceuticals Ltd | Equity | ₹147.68 Cr | 5.49% |
Lupin Ltd | Equity | ₹145.69 Cr | 5.41% |
Dr Reddy's Laboratories Ltd | Equity | ₹121.05 Cr | 4.50% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹111.58 Cr | 4.15% |
Cohance Lifesciences Ltd | Equity | ₹104.34 Cr | 3.88% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹81.02 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹78.32 Cr | 2.91% |
Wockhardt Ltd | Equity | ₹75.69 Cr | 2.81% |
Gland Pharma Ltd | Equity | ₹75.31 Cr | 2.80% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹75.24 Cr | 2.80% |
OneSource Specialty Pharma Ltd | Equity | ₹71.03 Cr | 2.64% |
Ipca Laboratories Ltd | Equity | ₹69.14 Cr | 2.57% |
Mankind Pharma Ltd | Equity | ₹67.1 Cr | 2.49% |
Sai Life Sciences Ltd | Equity | ₹66.72 Cr | 2.48% |
Alkem Laboratories Ltd | Equity | ₹66.23 Cr | 2.46% |
Fortis Healthcare Ltd | Equity | ₹65.9 Cr | 2.45% |
Syngene International Ltd | Equity | ₹47.02 Cr | 1.75% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹44.68 Cr | 1.66% |
Biocon Ltd | Equity | ₹32.37 Cr | 1.20% |
Alembic Pharmaceuticals Ltd | Equity | ₹29.46 Cr | 1.10% |
Sagility India Ltd | Equity | ₹20.79 Cr | 0.77% |
Treps | Cash - Repurchase Agreement | ₹20.68 Cr | 0.77% |
Deepak Nitrite Ltd | Equity | ₹19.09 Cr | 0.71% |
Neogen Chemicals Ltd | Equity | ₹17.3 Cr | 0.64% |
Laxmi Dental Ltd | Equity | ₹15.62 Cr | 0.58% |
Net Receivables / (Payables) | Cash | ₹-3.67 Cr | 0.14% |
Zydus Lifesciences Ltd | Equity | ₹2.02 Cr | 0.08% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.23 Cr | 0.01% |
Large Cap Stocks
32.77%
Mid Cap Stocks
37.27%
Small Cap Stocks
26.10%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,636.92 Cr | 98.01% |
Basic Materials | ₹36.39 Cr | 1.35% |
Standard Deviation
This fund
16.50%
Cat. avg.
16.03%
Lower the better
Sharpe Ratio
This fund
0.85
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since July 2018
ISIN INF769K01EA2 | Expense Ratio 1.94% | Exit Load 1.00% | Fund Size ₹2,691 Cr | Age 7 years | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹1,95,338 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments